B&K Corporation Limited (B&K Corp) will hold its 2025 annual general meeting on 22 June 2026 at the Metropark Hotel Yingkun Beijing. Shareholders on record as of the close of business 22 June 2026 may attend; the H-share register will be closed from 16–22 June.

Key proposals under consideration:

• Statutory Reports – Directors’, Board and Supervisory Committee work reports, the 2025 annual report and audited financial statements.

• Auditor Re-appointment – Renewal of Ernst & Young’s mandate for FY 2026 with audit fees estimated at RMB1.50–1.80 million.

• Profit Distribution – The Board proposes no final dividend for FY 2025 as no distributable profit was recorded.

• Corporate Governance Updates – Amendments to the Rules of Procedure for General Meetings and Board Meetings; replacement of the Supervisory Committee with an enhanced Audit Committee framework and related revisions to the Articles of Association.

• Capital Authorities  – General mandate to issue up to 20% of existing share capital (excluding any treasury shares).  – General mandate to repurchase up to 10% of H shares; repurchased shares may be cancelled or held as treasury stock in line with PRC and Hong Kong regulations.

• Proposed Change of Name – From “華芢生物科技(青島)股份有限公司” to “青城新藥生物科技(青島)股份有限公司”, leaving the English name B&K Corporation Limited unchanged.

Other items include approval of a revised profit-distribution policy, authorization for the Board to fix auditor remuneration, and routine renewals of internal governance rules.

As of the latest practicable date (21 May 2026) B&K Corp had 117.66 million issued shares, comprising 83.02 million H shares and 34.64 million unlisted shares. Completion of the proxy form is required by 10:00 a.m. on 21 June 2026 for shareholders unable to attend in person.